Your AI-Trained Oncology Knowledge Connection!
Michael L. Wang, MD, explains the biologic underpinnings of MCL as well as the treatment options for patients with MCL. The discussion is based on a case scenario of a patient with stage III intermediate-risk disease, and the factors that Wang would use when choosing the best treatment regimen for this patient.
Ibrutinib continues to be the standard of care for the treatment of relapsed/refractory patients with mantle cell lymphoma since its FDA approval in 2013, and long-term follow-up data of the Bruton's tyrosine kinase (BTK) inhibitor continue to demonstrate its clinical activity. In this interview with Targeted Oncology, an expert in the field sheds light on the impact of BTK inhibition on the treatment landscape.<br />
The potential synergy of new agents with other treatment strategies, including immunotherapeutic and targeted approaches, is currently being investigated in various clinical trials, with the hope of identifying combinations that will lead to longer responses and improvements in duration of response for patients with MCL.
Effective management of mantle cell lymphoma requires awareness of current therapeutic approaches for a wide range of patient populations, clinical trials supporting the use of therapy in the frontline or relapsed/refractory settings, newer therapeutic options and strategies, and emerging therapies to improve patient outcomes​​​​​​.
Due to the diversity of disease presentation, together with new iterations of guidelines for MCL diagnosis, staging, and risk, there is no standardized therapeutic approach. Treatment decisions are currently guided by several factors, including patient age, level of fitness, presence of symptoms, risk category, proliferative index, and cell variant, which means it is important to accurately diagnose, stage, and assess risk in patients with MCL
